ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

3,4-ジヒドロ-2(1H)-イソキノリンカルボイミドアミド

Debrisoquine

HCID 2966
ノート反応
基本情報名称と識別子物性化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1131-64-2
標準SMILES
N=C(N)N1CCc2ccccc2C1
InChIKey
JWPGJSVJDAJRLW-UHFFFAOYSA-N
分子式
C10H13N3
平均分子量
175.23 g/mol
単同位体質量
175.11094743

名称と識別子

優先名称
Debrisoquine
IUPAC
3,4-dihydro-1H-isoquinoline-2-carboximidamide
現地名
3,4-ジヒドロ-2(1H)-イソキノリンカルボイミドアミド
英語名
debrisoquine
分子式
C10H13N3
分子量
175.23

名称と別名

DebrisoquineDebrisoquin1131-64-2DebrisochinumDebrisoquinaDebrisoquinum2(1H)-Isoquinolinecarboximidamide, 3,4-dihydro-1,2,3,4-tetrahydroisoquinoline-2-carboximidamide3,4-dihydro-1H-isoquinoline-2-carboximidamideX31CDK040EDTXSID7022885CHEBI:34665
名称をさらに表示
3,4-ジヒドロ-2(1H)-イソキノリンカルボイミドアミドイソカラミジンデブリソキン1,2,3,4-テトラヒドロイソキノリン-2-カルボキシミドアミドebrisoquinDebrisochinDebrisoquine Monomer3,4-Dihydro-2(1H)-isoquinolinecarbimidamide3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXAMIDINE3,4-Dihydro-2(1H)-isoquinolinecarboximidamide
RefChem:388913DTXCID202885C02CC04214-470-1IsocaramidineTendor3,4-dihydroisoquinoline-2(1H)-carboximidamide3,4-Dihydro-2(1H)-isoquinolinecarboxamidine

データベース識別子

CAS
1131-64-2
PubChem CID
2966
DTXSID
DTXSID7022885
ChEMBL
CHEMBL169901
ChEBI
CHEBI:34665
UNII
X31CDK040E
EC Number
214-470-1
Nikkaji
J7.269I

物性

構造計算による物性

XLogP
0.8
極性表面積
53.1 Ų
水素結合供与体数
2
水素結合受容体数
1
回転可能結合数
1
重原子数
13
形式電荷
0
複雑度
202

実験および物理化学的性質

LogP · 2 件

0.75

0.75

Melting Point · 2 件

278-280 °C

278 - 280 °C

Physical DescriptionSolid

物理化学的性質

融点
278 · 278-280 °C
沸点
309.8 · 309.8±52.0 °C(Predicted)
比重(密度)
1.24 · 1.24±0.1 g/cm3(Predicted)
酸解離定数(Pka)
11.9 · pKa 11.9 (Uncertain)

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system;C02 - Antihypertensives;C02C - Antiadrenergic agents, peripherally acting;C02CC - Guanidine derivatives;C02CC04 - Debrisoquine

QC - Cardiovascular system;QC02 - Antihypertensives;QC02C - Antiadrenergic agents, peripherally acting;QC02CC - Guanidine derivatives;QC02CC04 - Debrisoquine

Pharmacodynamics · 1 件

Debrisoquin is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Mechanism of Action · 1 件

Debrisoquin acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, debrisoquin suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, debrisoquin lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.

Metabolism/Metabolites · 2 件

Hepatic.

Debrisoquine has known human metabolites that include 4-Hydroxydebrisoquine.

MeSH Pharmacological Classification · 3 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

関連反応

2 件
反応記録を作成
HRID 542286 の反応式
HRID 542286生成物としてuspto-grants-1987_04
HRID 2231166 の反応式
HRID 2231166生成物としてuspto-grants-1988_11

化合物ノート

読み込み中…

このページの内容基本情報名称と識別子物性化学と産業関連反応化合物ノート

Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Cellular LocationsCytoplasm;Extracellular

応用分野

使用Antihypertensive.

上流・下流製品情報

上流原料

1,2,3,4-テトラヒドロ-7-メトキシイソキノリン塩酸塩

サプライヤー13 社

Syntechem Co.,Ltd[email protected]
湖北扬信医药科技有限公司15347293736 · [email protected]
BOC Sciences16314854226; +8616314854226 · [email protected]
陕西缔都医药化工有限公司029-029-81120477 17792793610 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
河北贞佳新材料有限公司0319-5925599 13315915972 · [email protected]
湖北扬信医药科技有限公司15374522761 · [email protected]
华阴市赛普生物科技有限公司13892502238 · [email protected]
湖北信康医药化工有限公司027-027-59308705 18871579363 · [email protected]
TargetMol中国(陶术生物)4008200310 15002144251 · [email protected]
DAYANG CHEM (HANGZHOU) CO.,LTD+86-88938639 +86-17705817739 · [email protected]
Shaanxi Dideu Medichem Co. Ltd+86-17392712779 · [email protected]
南京世洲生物科技有限公司025-85563444 15850508050 · [email protected]